Global Merkel Cell Carcinoma Disease Treatment Market (2021 To 2026)

DUBLIN, March 1, 2022 /PRNewswire/ — The “Merkel Cell Carcinoma Disease Treatment Market – Forecast 2021 to 2026” report has been added to from ResearchAndMarkets.com offer.

The Merkel Cell Carcinoma Disease Treatment Market is expected to grow at a CAGR of 3.37% during the forecast period to reach US$3.782 billion by 2026, US$2.999 billion in 2019.

Merkel cell carcinoma (MCC) is a rare skin cancer that develops from malignant cancer cells. After melanoma, Merkel cell carcinoma is the second most common cause of death from skin cancer. Merkel cell cancer is caused by a weakened immune system and excessive sun exposure.

One of the key drivers driving the Merkel cell carcinoma disease treatment market over the forecast period is the growing number of Merkel cell carcinoma cases globally. The increase in cases has influenced the demand for new drugs for the treatment of Merkel cell carcinoma. Additionally, strong adoption of immunotherapy and favorable reimbursement are seen as encouraging indicators for the growth of Merkel cell carcinoma treatment. The market is expected to grow owing to the increase in research and development initiatives for the treatment of Merkel cell carcinoma.

Merkel cell carcinoma treatment market growth is limited by high treatment costs, cancellation of late-stage clinical trials, lack of public awareness, and side effects during the forecast period. Nausea, skin changes, diarrhea, painful sores in the throat and mouth, exhaustion, dry mouth or thick saliva are all side effects of external radiation therapy. The negative effects of radiation are transient, although some infrequent significant side effects may become permanent. Radiation therapy to the chest can sometimes cause lung damage, which can lead to breathing problems and shortness of breath.

Key developments

Nantkwest, Inc. (Immunitybio) announced the initiation of a Phase 2 clinical study of triple combination immunotherapy for the treatment of Merkel cell cancer in January 2019. KEYTRUDA was approved by the FDA in December 2018 for the treatment of pediatric and adult patients with locally advanced metastatic or recurrent Merkel cell carcinoma. At July 9, 2019, the Patient Advocate Foundation, a non-profit organization, provided funds to MCC patients to help pay for treatment-related travel costs. Once accepted, the financial fund will pay $450 one-time help to cover transportation costs to and from treatment appointments. According to the Fred Hutchinson Cancer Research Center, a multidisciplinary team from University of Washington and the Fred Hutchinson Cancer Research Center was awarded a five-year contract, $12 million grant to study Merkel cell cancer on April 16, 2019.

By therapy, the Merkel cell carcinoma disease treatment market is segmented into chemotherapy, radiotherapy, combination therapies, surgical excision, immunotherapy and others. Etoposide, cisplatin, carboplatin and topotecan are the different types of chemotherapy. Due to increasing research and reimbursement, the chemotherapy segment is expected to dominate the market over the projected period. Pembrolizumab and avelumab are two types of immunotherapy drugs. Due to the approval of immune checkpoint inhibitors, immunotherapy is expected to increase at a high rate during the forecast period.

By type of test, the Merkel cell carcinoma disease treatment market is segmented into computerized axial tomography, positron emission tomography, biopsy test, immunohistochemistry test and others. PET scans are effective and can be used to assess the presence of disease or other disorders in organs and/or tissues.

By end users, the Merkel cell carcinoma disease treatment market is segmented into hospitals, home care, surgical centers, specialty clinics and others. The preference for hospitals is expected to fuel the growth of the segment owing to the availability of innovative technologies and a large number of facilities available at a single location.

By geography, the Merkel cell carcinoma disease treatment market is segmented into five regions North America, Europe, South America, Middle East and Africaand Asia Pacific Regions. Due to increasing cases of skin cancer and favorable government regulations as well as modern healthcare facilities, North America will hold the largest market share for Merkel cell carcinoma therapy during the projected period, followed by Europe. Due to increasing government programs and a rapidly aging population, Asia Pacific has become the fastest growing regional category in terms of revenue. Furthermore, China and Australia find an increase in the incidence of Merkel cell carcinoma, increasing the need for treatment in these countries.

Information on COVID-19

Due to the COVID-19 pandemic, lockdown measures have been put in place, preventing patient movement and likely identification and overburdening healthcare systems. Small practices have closed completely, while larger businesses are currently responding to emergencies. This, in turn, will have a major impact on the Merkel cell carcinoma market. The COVID 19 outbreak would result in an extremely slow turnaround time for patients undergoing select procedures.

Main topics covered:

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS
4.1. Market factors
4.2. Market constraints
4.3. Analysis of the five forces of carriers
4.3.1. Bargaining power of suppliers
4.3.2. Bargaining powers of buyers
4.3.3. The threat of substitutes
4.3.4. The threat of new entrants
4.3.5. Competitive rivalry in the industry
4.4. Industry Value Chain Analysis

5. MERKEL CELL CARCINOMA DISEASE TREATMENT MARKET, BY THERAPY
5.1. introduction
5.2. Chemotherapy
5.3. Immunotherapy
5.4. Surgical excision
5.5. Radiotherapy
5.6. Combination therapy
5.7. Others

6. MERKEL CELL CARCINOMA DISEASE TREATMENT MARKET, BY TEST TYPE
6.1. introduction
6.2. Computerized axial computed tomography
6.3. Positron emission tomography scanner
6.4. Biopsy test
6.5. Immunohistochemistry test
6.6. Others

7. MERKEL CELL CARCINOMA DISEASE TREATMENT MARKET, BY END USERS
7.1. introduction
7.2. Hospitals
7.3. Home Care
7.4. Specialized clinics and surgical centers
7.5. Others

8. MERKEL CELL CARCINOMA DISEASE TREATMENT MARKET, BY GEOGRAPHY

9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Key Players and Strategic Analysis
9.2. Emerging players and lucrative market
9.3. Mergers, acquisitions, agreements and collaborations
9.4. Supplier Competitiveness Matrix

10. COMPANY PROFILES
10.1. Merck KGaA
10.2. Pfizer Inc.
10.3. Takeda Oncology (Millennium Pharmaceuticals Inc.)
10.4. Ono Pharmaceutical Co. Ltd
10.5. Bristol-Myers Squibb Company
10.6. OncoSec Medical Incorporated
10.7. McKesson Corporation
10.8. Amgen Inc.
10.9. Organic Immunity (NantKwest)

For more information on this report visit https://www.researchandmarkets.com/r/e018ae

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets